The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-01

Study Completion Date

2020-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To report the possible role of S.B 8.4% in the treatment of COVID-19pneumonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NAC for Attenuation of COVID-19 Symptomatology

NCT05074121

Covid19 COVID-19 Pneumonia COVID-19 Respiratory Infection +5 more

UNKNOWN PHASE2

COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising

NCT04433039

COVID

COMPLETED

Prognostic Significance of COVID-19 MSCT Chest Findings on Short Term Disease Progression

NCT05235373

COVID-19 Infection Viral

COMPLETED

Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study

NCT04365764

Covid-19 ARDS Pneumonia

COMPLETED

Predictors of COVID-19 Infection and Disease Progression

NCT04484597

Positive COVID-19 by PCR

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sodium Bicarbonate

Inhalation of Sodium Bicarbonate 8.4% via nebulizer

Group Type OTHER

Sodium Bicarbonate

Intervention Type DRUG

Inhalation of Sodium Bicarbonate 8.4% via nebulizer

Control

placebo

Group Type PLACEBO_COMPARATOR

Sodium Bicarbonate

Intervention Type DRUG

Inhalation of Sodium Bicarbonate 8.4% via nebulizer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sodium Bicarbonate

Inhalation of Sodium Bicarbonate 8.4% via nebulizer

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years.
* Fever ≥ 38º C with upper respiratory tract manifestations, generalized bone ache with or without gastrointestinal symptoms as diarrhea.
* Chest CT with signs suggestive of COVID-19.
* Mild and moderate cases of COVID-19 pneumonia with respiratory and hemodynamic stability. - High C reactive protein (CRP).- With or without history of contact with index case who is isolated in a governmental hospital assigned for treatment of patients proved to have RT-PCR positive test for COVID-19
* With or without abnormalities in the total or differential white cell count.
* Welling to sign a fully informed consent.

Exclusion Criteria

* Severe and critical illness with respiratory failure and/ or hemodynamic instability.
* CT with pleural effusion with or without lung cavitation.
* Other organ failure.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No